THAR Key Statistics, Chart & Performance
The current stock price of THAR is 2.32 USD. In the past month the price increased by 3.11%. In the past year, price increased by 12.08%.
THAR Latest News, Press Relases and Analysis
THAR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24 | 400.88B | ||
| AMGN | AMGEN INC | 14.97 | 176.29B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.28 | 115.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.76 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.29B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.44 | 25.64B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 22.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B | ||
| INCY | INCYTE CORP | 16 | 20.16B |
Related stock screener links
About THAR
Company Profile
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Company Info
THARIMMUNE INC
1200 Route 22 East
Bridgewater NEW JERSEY US
Employees: 2
Phone: 13027432995
THARIMMUNE INC / THAR FAQ
Can you describe the business of THARIMMUNE INC?
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
What is the current price of THAR stock?
The current stock price of THAR is 2.32 USD. The price increased by 4.5% in the last trading session.
What is the dividend status of THARIMMUNE INC?
THAR does not pay a dividend.
How is the ChartMill rating for THARIMMUNE INC?
THAR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for THARIMMUNE INC?
THARIMMUNE INC (THAR) will report earnings on 2026-03-25, before the market open.
What is the ownership structure of THARIMMUNE INC (THAR)?
You can find the ownership structure of THARIMMUNE INC (THAR) on the Ownership tab.
What is the Short Interest ratio of THARIMMUNE INC (THAR) stock?
The outstanding short interest for THARIMMUNE INC (THAR) is 2.04% of its float.
THAR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to THAR. When comparing the yearly performance of all stocks, THAR is a bad performer in the overall market: 78.99% of all stocks are doing better.
THAR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to THAR. The financial health of THAR is average, but there are quite some concerns on its profitability.
THAR Financial Highlights
Over the last trailing twelve months THAR reported a non-GAAP Earnings per Share(EPS) of -4.11. The EPS increased by 77.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.03% | ||
| ROE | -167.66% | ||
| Debt/Equity | 0.03 |
THAR Forecast & Estimates
7 analysts have analysed THAR and the average price target is 5.1 USD. This implies a price increase of 119.83% is expected in the next year compared to the current price of 2.32.